Header Logo

Connection

Ajaypal Singh to Renal Dialysis

Back to Details
This is a "connection" page, showing publications Ajaypal Singh has written about Renal Dialysis.
Ajaypal Singh
Connection Strength
6.949
Renal Dialysis
  1. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
    View in: PubMed
    Score: 0.767
  2. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem. Semin Dial. 2013 Sep-Oct; 26(5):531-4.
    View in: PubMed
    Score: 0.429
  3. Con: Randomized controlled trials (RCT) have failed in the study of dialysis methods. Nephrol Dial Transplant. 2013 Apr; 28(4):826-32; discussion 832.
    View in: PubMed
    Score: 0.423
  4. Pro: The value of randomized controlled studies in dialysis methods. Nephrol Dial Transplant. 2013 Apr; 28(4):834-5; discussion 835-6.
    View in: PubMed
    Score: 0.423
  5. Is there a deleterious effect of erythropoietin in end-stage renal disease? Kidney Int. 2011 Sep; 80(6):569-71.
    View in: PubMed
    Score: 0.379
  6. Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clin J Am Soc Nephrol. 2010 Aug; 5(8):1355-8.
    View in: PubMed
    Score: 0.352
  7. ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol. 2010 Apr; 21(4):543-6.
    View in: PubMed
    Score: 0.343
  8. Should we keep hemoglobin levels as a viable outcome measure? Nephrol News Issues. 2010 Mar; 24(3):15-6, 18.
    View in: PubMed
    Score: 0.341
  9. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008 Sep; 74(5):679-83.
    View in: PubMed
    Score: 0.298
  10. The optimal hemoglobin in dialysis patients- a critical review. Semin Dial. 2008 Jan-Feb; 21(1):1-6.
    View in: PubMed
    Score: 0.294
  11. Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant. 2023 07 31; 38(8):1890-1897.
    View in: PubMed
    Score: 0.216
  12. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). Am J Nephrol. 2023; 54(1-2):1-13.
    View in: PubMed
    Score: 0.209
  13. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
    View in: PubMed
    Score: 0.205
  14. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
    View in: PubMed
    Score: 0.199
  15. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
    View in: PubMed
    Score: 0.198
  16. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
    View in: PubMed
    Score: 0.157
  17. BP in Dialysis: Results of a Pilot Study. J Am Soc Nephrol. 2018 01; 29(1):307-316.
    View in: PubMed
    Score: 0.146
  18. Ferric pyrophosphate citrate (Triferic?) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015 Dec; 30(12):2019-26.
    View in: PubMed
    Score: 0.124
  19. Cognitive function and all-cause mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2015 Feb; 65(2):303-11.
    View in: PubMed
    Score: 0.117
  20. Sudden cardiac arrest in ESRD patients. Clin Nephrol. 2014 Feb; 81(2):121-31.
    View in: PubMed
    Score: 0.112
  21. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013 Jan 29; 80(5):471-80.
    View in: PubMed
    Score: 0.104
  22. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis. 2009 Sep; 54(3):498-510.
    View in: PubMed
    Score: 0.082
  23. Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions. Semin Nephrol. 2009 Mar; 29(2):105-12.
    View in: PubMed
    Score: 0.080
  24. Role of vitamin D in chronic kidney disease. Semin Nephrol. 2009 Mar; 29(2):113-21.
    View in: PubMed
    Score: 0.080
  25. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008; 110(4):c244-50.
    View in: PubMed
    Score: 0.078
  26. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95.
    View in: PubMed
    Score: 0.077
  27. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008 Dec; 74(12):1617-22.
    View in: PubMed
    Score: 0.076
  28. Acute coronary syndrome in ESRD patients. Kidney Int. 2009 Mar; 75(5):558-62.
    View in: PubMed
    Score: 0.076
  29. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007 Dec; 18(12):3184-91.
    View in: PubMed
    Score: 0.073
  30. Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim.
    View in: PubMed
    Score: 0.072
  31. The FDA black box for EPO: what should nephrologists do? Nephrol News Issues. 2007 May; 21(6):55-6, 58-9.
    View in: PubMed
    Score: 0.070
  32. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar; 18(3):975-84.
    View in: PubMed
    Score: 0.069
  33. Associations between demographic factors and provider structures on cost and length of stay for hemodialysis patients with vascular access failure. Clin J Am Soc Nephrol. 2006 May; 1(3):455-61.
    View in: PubMed
    Score: 0.065
  34. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease. Nephrol Nurs J. 2005 Mar-Apr; 32(2):199-206; quiz 207-8.
    View in: PubMed
    Score: 0.060
  35. Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. N Engl J Med. 2022 12 29; 387(26):2482-2485.
    View in: PubMed
    Score: 0.052
  36. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
    View in: PubMed
    Score: 0.050
  37. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
    View in: PubMed
    Score: 0.036
  38. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.